similarly used immunohistochemistry to find that high expression of Enhancer of Zeste Homolog 2 (EZH2) in high-grade NENs was associated with poorer OS and was also significantly correlated with histological manifestations of NEC, proposing that EZH2 could be used as a biomarker to differentiate NET G3 from NEC (22). The gene discussed is EZH2; the disease is neuroendocrine carcinoma.